title: Customizing Functionality and Payload Delivery for Receptor-Engineered T Cells.
abstract: Adoptive immunotherapy using receptor engineering to achieve specific tumor targeting by T cells holds much promise for advancing cancer therapy. Here, two studies by Boice et al. and Roybal et al. provide distinct and potentially complimentary approaches to improve the efficacy and curb potential toxicities of this approach.
authors.affiliation: Center for Cell Engineering and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: caklebanoff@gmail.com.
authors.forename: Christopher A
authors.initials: CA
authors.lastname: Klebanoff
authors.affiliation: Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA; Center for Cell-Based Therapy, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: restifo@nih.gov.
authors.forename: Nicholas P
authors.initials: NP
authors.lastname: Restifo
mesh_terms: D006801:Humans; D016219:Immunotherapy, Adoptive; D009369:Neoplasms / Q000628:therapy; D011948:Receptors, Antigen, T-Cell; D013601:T-Lymphocytes
chemical_list: D011948:Receptors, Antigen, T-Cell